1. A phase 2a, randomized, double‐blind, placebo‐controlled, three‐arm, parallel‐group study to assess the efficacy, safety, tolerability and pharmacodynamics of PF‐06835919 in patients with non‐alcoholic fatty liver disease and type 2 diabetes. Issue 4 (17th January 2023) Authors: Saxena, Aditi R.; Lyle, Stephanie‐An; Khavandi, Kaivan; Qiu, Ruolun; Whitlock, Mark; Esler, William P.; Kim, Albert M. Journal: Diabetes, obesity & metabolism Issue: Volume 25:Issue 4(2023) Page Start: 992 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A randomised, placebo-controlled clinical trial with the α2/3/5 subunit selective GABAA positive allosteric modulator PF-06372865 in patients with chronic low back pain. Issue 9 (September 2018) Authors: Gurrell, Rachel; Dua, Pinky; Feng, Gang; Sudworth, Maria; Whitlock, Mark; Reynolds, David S.; Butt, Richard P. Journal: Pain Issue: Volume 159:Issue 9(2018) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Analgesic potential of PF-06372865, an α2/α3/α5 subtype-selective GABAA partial agonist, in humans. (August 2019) Authors: van Amerongen, Guido; Siebenga, Pieter S.; Gurrell, Rachel; Dua, Pinky; Whitlock, Mark; Gorman, Donal; Okkerse, Pieter; Hay, Justin L.; Butt, Richard P.; Groeneveld, Geert Jan Journal: British journal of anaesthesia Issue: Volume 123:Number 2(2019) Page Start: e194 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Pharmacology in translation: the preclinical and early clinical profile of the novel α2/3 functionally selective GABAA receptor positive allosteric modulator PF‐06372865. (18th January 2018) Authors: Nickolls, Sarah A; Gurrell, Rachel; van Amerongen, Guido; Kammonen, Juha; Cao, Lishuang; Brown, Adam R; Stead, Clara; Mead, Andy; Watson, Christine; Hsu, Cathleen; Owen, Robert M; Pike, Andy; Fish, Rebecca L; Chen, Laigao; Qiu, Ruolun; Morris, Evan D; Feng, Gang; Whitlock, Mark; Gorman, Donal; va... Journal: British journal of pharmacology Issue: Volume 175:Number 4(2018) Page Start: 708 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Reflections on the Evolution of Conflict Early Warning. Issue 1 (28th March 2022) Authors: Muggah, Robert; Whitlock, Mark Journal: Stability Issue: Volume 10:Issue 1(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Response to "Treating patients rather than their functional neuroimages" (Br J Anaesth 2018; 121: 969–71). (August 2019) Authors: Wanigasekera, Vishvarani; Wartolowska, Karolina; Huggins, John P.; Duff, Eugene P.; Vennart, William; Whitlock, Mark; Massat, Natalie; Pauer, Lynne; Rogers, Peter; Hoggart, Barbara; Tracey, Irene Journal: British journal of anaesthesia Issue: Volume 123:Number 2(2019) Page Start: e166 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Safety, Tolerability, and Pharmacokinetics of Multiple Repeated Oral Doses of the α2/3/5‐Subtype Selective GABAA‐Positive Allosteric Modulator PF‐06372865 in Healthy Volunteers. Issue 7 (19th January 2021) Authors: Gurrell, Rachel; Whitlock, Mark; Wei, Hua; Shen, Zhongzhou; Ogden, Adam Journal: Clinical pharmacology in drug development Issue: Volume 10:Issue 7(2021) Page Start: 756 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗